Selected Publications
Freed-Pastor WA, Lambert LJ, Ely ZA, Pattada NB, Bhutkar A, Eng G, Mercer KL, Garcia AP, Lin L, Rideout WM 3rd, Hwang WL, Schenkel JM, Jaeger AM, Bronson RT, Westcott PMK, Hether TD, Divakar P, Reeves JW, Deshpande V, Delorey T, Phillips D, Yilmaz OH, Regev A, Jacks T. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell. 2021 Oct 11;39(10):1342-60.e14. PMID: 34358448; PMCID: PMC8511341
Ely ZA, Kulstad ZJ, Gunaydin G, Addepalli S, Verzani EK, Casarrubios M, Clauser KR, Wang X, Lippincott IE, Louvet C, Schmitt T, Kapner KS, Agus MP, Hennessey CJ, Cleary JM, Hadrup SR, Klaeger S, Su J, Jaeger AM, Wolpin BM, Raghavan S, Smith EL, Greenberg PD, Aguirre AJ, Abelin JG, Carr SA, Jacks T, Freed-Pastor WA. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Science. 2025. May 8;388(6747); doi: 10.1126/SCIENCE.ADK3487.
|
Pancreatic cancer–restricted cryptic antigens are targets for T cell recognition
Translation of the noncoding genome in cancer can generate cryptic (noncanonical) peptides capable of presentation by human leukocyte antigen class I (HLA-I); however, the cancer specificity and immunogenicity of noncanonical HLA-I–bound peptides (ncHLAp)...www.science.org |
Synopsis of Ely et al. 2025 by Accelerating Cancer Immunotherapy Research (ACIR):
Hidden gems: cryptic antigens as novel therapeutic targets in pancreatic cancer